StocksFundsScreenerSectorsWatchlists
NVTA

NVTA - Invitae Corp Stock Price, Fair Value and News

0USD0Market Closed
0

NVTA Stock Price

View Fullscreen

NVTA RSI Chart

NVTA Valuation

EV/EBITDA

-0.77

NVTA Price/Sales (Trailing)

NVTA Profitability

Operating Margin

27.13%

EBT Margin

-301.93%

Return on Equity

-5.5M%

Return on Assets

-269.22%

NVTA Fundamentals

NVTA Revenue

Revenue (TTM)

481.6M

Rev. Growth (Yr)

-9.21%

Rev. Growth (Qtr)

0.59%

NVTA Earnings

Earnings (TTM)

-1.4B

Earnings Growth (Yr)

-212.83%

Earnings Growth (Qtr)

-356.2%

Breaking Down NVTA Revenue

Last 30 days

-50%

Last 90 days

-98%

Trailing 12 Months

-99.3%

How does NVTA drawdown profile look like?

NVTA Financial Health

Current Ratio

2.39

Debt/Equity

43.4K

Debt/Cashflow

-0.21

NVTA Investor Care

Shares Dilution (1Y)

17.95%

Diluted EPS (TTM)

-6.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023510.0M493.9M481.6M0
2022480.5M500.8M520.0M516.3M
2021319.0M389.1M434.8M460.4M
2020240.5M233.2M245.5M279.6M
2019160.6M176.8M195.9M216.8M
201885.6M108.5M127.7M147.7M
201731.4M40.2M52.1M68.2M
201611.1M14.9M19.0M25.0M
20152.7M4.2M6.1M8.4M
2014512.0K876.0K1.2M1.6M
2013000148.0K

Tracking the Latest Insider Buys and Sells of Invitae Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 20, 2023
brida thomas
sold (taxes)
-11,277
0.648
-17,404
see remarks
Dec 20, 2023
nussbaum robert l
sold (taxes)
-11,277
0.648
-17,404
chief medical officer
Nov 13, 2023
sholehvar david
acquired
-
-
850,000
chief operating officer
Oct 18, 2023
brida thomas
acquired
-
-
229,500
see remarks
Oct 02, 2023
schrank ana j.
acquired
-
-
850,000
chief financial officer
Sep 23, 2023
guigley robert m.
acquired
-
-
850,000
chief commercial officer
Jun 13, 2023
brida thomas
sold
-9,747
1.377
-7,079
see remarks
Jun 13, 2023
nussbaum robert l
sold
-9,757
1.377
-7,086
chief medical officer
May 16, 2023
werner robert f.
sold
-25,855
1.1993
-21,559
chief accounting officer
May 16, 2023
knight kenneth d.
sold
-54,486
1.1993
-45,432
chief executive officer

1–10 of 50

Which funds bought or sold NVTA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
ARK Investment Management LLC
sold off
-100
-20,402,800
-
-%
Apr 18, 2024
PayPay Securities Corp
added
64.5
-6,407
190
0.01%
Apr 16, 2024
TOTH FINANCIAL ADVISORY CORP
sold off
-100
-242
-
-%
Apr 16, 2024
Register Financial Advisors LLC
new
-
2.00
2.00
-%
Apr 15, 2024
Security National Bank
sold off
-100
-66.00
-
-%
Apr 15, 2024
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
sold off
-100
-9,978
-
-%
Apr 15, 2024
Sunbelt Securities, Inc.
unchanged
-
-67.00
1.00
-%
Apr 15, 2024
WEST PACES ADVISORS INC.
unchanged
-
-9.00
-
-%
Apr 15, 2024
Concurrent Investment Advisors, LLC
new
-
6,828
6,828
-%
Apr 12, 2024
BOURNE LENT ASSET MANAGEMENT INC
sold off
-100
-360,159
-
-%

1–10 of 43

Are Funds Buying or Selling NVTA?

Are funds buying NVTA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NVTA
No. of Funds

Unveiling Invitae Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
nikko asset management americas, inc.
5.85%
16,764,480
SC 13G/A
Feb 13, 2024
vanguard group inc
5.12%
14,660,153
SC 13G/A
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
5.85%
16,764,480
SC 13G/A
Jan 29, 2024
ark investment management llc
11.36%
32,550,683
SC 13G/A
Jan 29, 2024
blackrock inc.
6.7%
19,258,772
SC 13G/A
Aug 30, 2023
flynn james e
4.9%
93,062,106
SC 13G
Feb 14, 2023
casdin capital, llc
3.72%
9,038,388
SC 13G/A
Feb 10, 2023
ark investment management llc
11.15%
27,072,844
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
7.10%
17,256,161
SC 13G/A
Feb 09, 2023
vanguard group inc
9.30%
22,587,955
SC 13G/A

Recent SEC filings of Invitae Corp

View All Filings
Date Filed Form Type Document
Apr 04, 2024
8-K
Current Report
Mar 06, 2024
8-K
Current Report
Feb 21, 2024
25-NSE
25-NSE
Feb 14, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
8-K
Current Report
Feb 05, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Invitae Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
174.9B
23.9B
-6.84% -7.21%
36.87
7.32
-10.33% -33.23%
39.7B
3.7B
-10.56% -2.00%
47
10.85
8.72% 24.44%
38.8B
6.7B
-10.14% -4.66%
31.4
5.76
-2.81% -6.58%
13.9B
9.3B
-2.39% -12.25%
16.33
1.51
-6.38% -9.73%
11.7B
4.1B
-14.60% 12.19%
24.62
2.83
3.86% -2.39%
11.5B
2.5B
2.50% -7.62%
-56.42
4.61
19.93% 67.26%
11.5B
1.9B
-4.08% 93.54%
40.69
6.1
29.17% 15.26%
10.5B
1.1B
-4.43% 64.16%
-24.22
9.73
31.99% 20.63%
MID-CAP
2.6B
929.2M
-20.98% -28.89%
1.7K
2.78
28.93% 111.61%
2.0B
563.9M
-7.02% -33.76%
-4.23
3.6
25.45% 26.76%
SMALL-CAP
417.9M
280.3M
-18.17% -10.74%
-2.2
1.49
-12.89% -148.37%
87.2M
31.2M
7.83% -86.85%
-0.99
2.79
5.03% -1.81%
43.6M
9.2M
-0.56% -37.52%
-2.61
4.76
11.85% 44.12%
5.8M
9.0M
-24.44% -66.67%
-0.8
0.64
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Invitae Corp News

Latest updates
Yahoo Movies Canada14 Apr 202401:02 pm
InvestorPlace2 months ago
The Motley Fool2 months ago

Invitae Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.6%121,241,000120,532,000117,356,000122,454,000133,536,000136,622,000123,691,000126,121,000114,395,000116,312,000103,621,000100,431,00068,728,00046,191,00064,248,00066,285,00056,511,00053,475,00040,553,00045,356,00037,366,000
Cost Of Revenue-6.0%82,186,00087,474,00088,442,00092,844,000116,956,000110,340,00097,116,00096,106,00087,741,00089,331,00075,491,00068,258,00046,643,00042,952,00040,422,00036,723,00032,120,00028,006,00021,254,00021,141,00020,441,000
Costs and Expenses217.4%1,101,429,000346,994,000292,727,000217,349,000423,487,0002,656,953,000336,924,000340,695,000307,707,000-12,297,000215,985,000--------71,260,00067,476,000
  S&GA Expenses-15.1%37,999,00044,732,00044,510,00046,795,00049,193,00062,749,00060,144,00062,205,00055,501,00056,964,00051,240,00048,877,00037,800,00039,520,00042,120,00034,575,00032,690,00030,779,00024,193,00019,206,00017,591,000
  R&D Expenses-8.6%58,336,00063,824,00061,978,00071,529,00087,177,000115,146,000128,236,000131,764,00097,511,000106,454,00080,358,00072,172,00037,802,00074,963,00055,668,00051,279,00046,951,00025,302,00017,994,00016,570,00015,776,000
EBITDA Margin-113.6%-2.62-1.22-5.73-5.72-5.91-5.98-0.77-0.62-0.98-0.89-2.04-2.31---------
Interest Expenses-2.8%5,850,0006,020,00011,496,00014,598,00014,145,00014,019,00013,985,00014,031,00014,069,00013,407,0008,393,00012,522,0006,308,0005,485,0005,451,0005,350,0002,833,0002,121,0002,108,0002,103,0001,844,000
Income Taxes-567.9%-6,171,000-924,000-960,000-5,334,500-1,068,000-3,600,000-34,920,000-7,649,000-5,848,000-16,560,000-6,800,000-109,500,000--2,600,000---8,700,000-3,950,000--2,800,000-
Earnings Before Taxes-357.1%-948,278,000-207,435,000-193,143,000-105,170,000-302,224,000-2,527,024,000-216,779,000-212,773,000-204,024,000117,226,000-116,292,000-343,838,000-102,902,000-169,003,000-98,527,000-82,705,000-87,407,000-52,626,000--32,641,000-31,723,000
EBT Margin-84.6%-3.02-1.64-6.13-6.10-6.27-6.31-1.07-0.90-1.26-1.15-2.29-2.55---------
Net Income-356.2%-942,107,000-206,511,000-192,183,000-99,817,000-301,156,000-2,523,461,000-181,859,000-205,124,000-198,176,000133,786,000-109,492,000-234,338,000-102,902,000-166,403,000-98,527,000-76,905,000-78,707,000-48,676,000-37,677,000-29,841,000-31,723,000
Net Income Margin-84.8%-2.99-1.62-6.11-6.02-6.18-6.21-0.94-0.82-0.94-0.80-1.92-2.15---------
Free Cashflow-22.2%-68,825,000-56,322,000-35,722,000-86,990,000-140,117,000-150,811,000-168,391,000-195,090,000-180,431,000-143,048,000-95,951,000-122,454,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-64.9%5351,5231,6921,9542,0262,2914,7684,9205,0714,9953,8733,430913970791782790503476283284
  Current Assets-16.1%3784515046937308941,0311,1791,3661,644780454415471357442509288321165167
    Cash Equivalents-29.1%1582231612572173043259349221,10820413111317597.00158473253258118106
  Inventory3.9%22.0021.0019.0030.0030.0049.0043.0034.0031.0030.0031.0032.00---7.00-----
  Net PPE-28.9%65.0092.0095.0010911413313011510183.0073.0066.0046.0043.0041.0038.0032.0029.0026.0028.0029.00
  Goodwill-------2,2832,2832222,0611,9261,86421121151.0012710026.0050.0050.0047.00
Liabilities-6.1%1,6191,7241,7281,8521,8671,9051,9241,9411,9642,3411,4971,454497506465402387161160121105
  Current Liabilities4.2%15815219010811313916814415613414612210112712182.0069.0040.0042.0036.0043.00
  Long Term Debt-3.7%1,1281,1711,1691,4711,4691,4671,4661,4641,4621,461343284280276272269-75.0075.0074.0050.00
    LT Debt, Non Current-3.7%1,1281,1711,1691,4711,4691,4671,4661,4641,4621,461343284280276272269-75.0075.0074.0050.00
Shareholder's Equity---0.001021593862,8444,7013,1072,6542,3761,9764170.000.003804049450.000.00179
  Retained Earnings-18.0%-6,169-5,227-5,021-4,800-4,729-4,428-1,904-1,722-1,517-1,319-1,453-1,360-1,126-1,023-857-758-681-603-554-516-486
  Additional Paid-In Capital0.9%5,0615,0184,9854,9314,8894,8154,7494,7014,6243,9733,8303,3371,5431,4871,1821,1381,086945871679666
Shares Outstanding-0.2%263264250246233232228228206204194135---------
Float------570---6,800---4,000---2,100---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-21.8%-66,897-54,905-34,398-82,066-128,702-134,689-147,543-175,903-165,052-129,325-89,520-113,580-62,166-60,394-62,360-47,266-36,696-32,725-28,366-15,473-18,080
  Share Based Compensation-14.4%25,99730,36429,19334,99060,41357,07946,82248,30725,43147,56258,77556,41821,20551,84629,27828,12228,28614,3175,22310,798-
Cashflow From Investing-95.6%5,117116,06473,878121,89143,797108,965-449,456170,503-20,324-80,701-273,558-312,292-5,674-83,417800-270,698-17,20025,133-17,54511,1846,530
Cashflow From Financing-486.0%-3,381876-135,768599-1,6913,770-9207,031-7351,123,553436,091444,2336,415221,7945512,341273,8482,462186,12016,02864,100

NVTA Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 121,241$ 133,536$ 359,129$ 393,849
Operating expenses:    
Cost of revenue82,186116,956258,102324,412
Research and development58,33687,177184,138330,559
Selling and marketing37,99949,193127,241172,086
General and administrative45,61944,939160,826147,221
Goodwill and IPR&D impairment0002,313,047
Restructuring, impairment and other costs877,289125,2221,010,843130,039
Total operating expenses1,101,429423,4871,741,1503,417,364
Loss from operations(980,188)(289,951)(1,382,021)(3,023,515)
Other income (expense), net:    
Gain (loss) on extinguishment of debt, net2290(10,593)0
Debt issuance costs(845)0(20,704)0
Change in fair value of convertible senior secured notes33,463072,3860
Change in fair value of acquisition-related liabilities70(527)33715,666
Other income, net4,8432,39915,1053,971
Total other income, net37,7601,87256,53119,637
Interest expense(5,850)(14,145)(23,366)(42,149)
Net loss before taxes(948,278)(302,224)(1,348,856)(3,046,027)
Income tax benefit6,1711,0688,05539,551
Net loss$ (942,107)$ (301,156)$ (1,340,801)$ (3,006,476)
Net (loss) income per share, basic (in dollars per share)$ (3.42)$ (1.27)$ (5.09)$ (12.91)
Net (loss) income per share, diluted (in dollars per share)$ (3.42)$ (1.27)$ (5.09)$ (12.91)
Shares used in computing net loss per share, basic275,604237,974263,210232,889
Shares used in computing net loss per share, diluted275,604237,974263,210232,889
Test revenue    
Revenue:    
Total revenue$ 117,561$ 128,839$ 346,127$ 381,518
Other revenue    
Revenue:    
Total revenue$ 3,680$ 4,697$ 13,002$ 12,331

NVTA Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 158,007$ 257,489
Marketable securities96,566289,611
Accounts receivable82,50796,148
Inventory21,62730,386
Prepaid expenses and other current assets19,69219,496
Total current assets378,399693,130
Property and equipment, net65,446108,723
Operating lease assets61,639106,563
Restricted cash10,10010,030
Intangible assets, net01,012,549
Other assets19,53123,121
Total assets535,1151,954,116
Current liabilities:  
Accounts payable25,18513,984
Accrued liabilities84,72974,388
Operating lease obligations17,65014,600
Finance lease obligations3,9485,121
Total current liabilities158,419108,093
Operating lease obligations, net of current portion134,945134,386
Finance lease obligations, net of current portion8553,780
Convertible senior notes, net current portion26,9070
Debt0122,333
Convertible senior notes, net1,127,8301,470,783
Convertible senior secured notes (at fair value)196,2440
Deferred tax liability08,130
Other long-term liabilities2264,775
Total liabilities1,618,5191,852,280
Commitments and contingencies
Stockholders’ (deficit) equity:  
Common stock2925
Accumulated other comprehensive income (loss)25,378(80)
Additional paid-in capital5,061,1314,931,032
Accumulated deficit(6,169,942)(4,829,141)
Total stockholders’ (deficit) equity(1,083,404)101,836
Total liabilities and stockholders’ (deficit) equity$ 535,115$ 1,954,116
NVTA
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
 CEO
 WEBSITEinvitae.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES1700

Invitae Corp Frequently Asked Questions


What is the ticker symbol for Invitae Corp? What does NVTA stand for in stocks?

NVTA is the stock ticker symbol of Invitae Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Invitae Corp (NVTA)?

As of Wed Apr 17 2024, market cap of Invitae Corp is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVTA stock?

You can check NVTA's fair value in chart for subscribers.

What is the fair value of NVTA stock?

You can check NVTA's fair value in chart for subscribers. The fair value of Invitae Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Invitae Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Invitae Corp a good stock to buy?

The fair value guage provides a quick view whether NVTA is over valued or under valued. Whether Invitae Corp is cheap or expensive depends on the assumptions which impact Invitae Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVTA.

What is Invitae Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, NVTA's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVTA PE ratio will change depending on the future growth rate expectations of investors.